Meneldor

AI Verified

Location

Netherlands


Investor type

Venture Capital


Current investment status

00 00 00


Website

https://meneldor.nl/


Linkedin

00 00 00


Company address

Netherlands


Founding year

2016


Twitter

00 00 00


Facebook

00 00 00

Criteria Requirements Match
Regions
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Countries
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Sector
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Impact Area
00 00 00
Stage
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Ticket size
00 00 00
-
00 00 00
USD
00
Monetization model
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Product readiness
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Client types
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
00
Min. revenue
00 00 00
USD
00
Other
00 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 0000 00 00
-

Unlock Premium Insights

Discover how well you match with this investor and reach out on the Raise Better platform.

  • Advanced matching algorithm
  • Detailed compatibility scores
  • Priority investor access
Create Free Account
Company Description
INTRODUCTION Meneldor offers her customers the unique opportunity to co-invest alongside specialists, in exciting early stage Biotech and Pharma companies. A sector often considered as very risky and highly complex. Meneldor thoroughly studies the science behind her potential portfolio companies. If the science is sound, then all other key aspects; IP, medical need, addressable markets, competition, risk, management, financial needs, valuation, etc., are assessed. Only if a target company meets our selection criteria, Meneldor will invest and invite her co-investors to participate. INVESTMENT FOCUS Meneldor focuses on early stage biotech and pharma companies that (re)develop (New) Bio or Chemical Molecular Entities or Repurposed drugs, that have outstanding technology with strong IP, address significant unmet medical needs and attractive markets. We are especially scouting for companies that work on relatively low risk and high growth opportunities. We mainly invest in projects which are in preclinical, Phase I or early Phase II and in indications with preferably clear well defined clinical endpoints. Our geographic focus is Europe. CURRENT HOLDINGS AND PIPELINE Meneldor has a very exciting pipeline. Details will be shared only under NDA. Our current holdings are: 2016: Xenikos B.V. (Netherlands) 2017: Atriva Therapeutics GmbH (Germany) 2018: Aptamer Group Ltd (UK) 2019: LightOx Ltd (UK) 2021: TagWorks Pharma (Netherlands) 2022: Hemispherian (Norway)
Highlights
Over €100 million assets under management
Investing in low risk, high growth biotech
Founders with 25+ years of experience
Specializes in early stage Biotech and Pharma companies
Co-investment opportunity alongside specialists in biotech

Ready to raise better?

Create your Free Account!